A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Immatics Biotechnologies GmbH
M.D. Anderson Cancer Center
Boehringer Ingelheim
Janssen Research & Development, LLC
TOLREMO therapeutics AG
Revolution Medicines, Inc.
Pfizer
Erasca, Inc.
AbbVie
GlaxoSmithKline
Atavistik Bio, Inc
Zhejiang University
West China Hospital
Eisai Inc.
Daiichi Sankyo
Replimune Inc.
M.D. Anderson Cancer Center
Werewolf Therapeutics, Inc.
Baylor College of Medicine
ModernaTX, Inc.
Children's Hospital Los Angeles
EMD Serono
Tesaro, Inc.
M.D. Anderson Cancer Center
AbbVie
GlaxoSmithKline
AgonOx, Inc.
UNC Lineberger Comprehensive Cancer Center
Novartis
AbbVie
Bristol-Myers Squibb
Amgen
AstraZeneca
AstraZeneca
Tesaro, Inc.
GlaxoSmithKline
AbbVie
M.D. Anderson Cancer Center
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
HUYABIO International, LLC.
Albert Einstein College of Medicine
Exelixis
AbbVie
AbbVie
iTeos Therapeutics
AbbVie
Nuvectis Pharma, Inc.
AbbVie